Taysha Gene Therapies Inc

$2.98 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc. is a patient-centric gene therapy company. The Company is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

Stock Analysis

last close $3.03
1-mo return -40.9%
3-mo return -53.2%
avg daily vol. 256.59T
52-week high 26.99
52-week low 2.69
market cap. $139M
forward pe -
annual div. -
roe -140.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 40.6%

Subscribe now for daily local and international financial news